1
|
Thoms J, Soosaipillai A, Christensen E, Sykes J, Pintilie M, Diamandis E, Bristow R. Human Tissue Kallikrein (KLK) Expression and IMRT Response in Intermediate Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
2
|
Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol 2010; 22:877-883. [PMID: 20924077 DOI: 10.1093/annonc/mdq462] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Primary tumor levels of serine proteases of the kallikrein-related peptidases (KLK) family as well as urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 impact disease course in ovarian cancer. The changes in levels of these factors from primary tumor to omentum metastasis ('level differentials') could thus be associated with metastastic processes. PATIENTS AND METHODS Protein levels of seven tissue KLK (KLK5-8, 10, 11, 13), uPA, and PAI-1 were determined in extracts of primary tumor tissue and corresponding omentum metastasis of 54 ovarian cancer patients. RESULTS Higher level differentials of KLK5-8, 10-11, and uPA were associated with residual tumor >10 mm. Residual tumor and larger level differentials of KLK5-7, 10, and uPA were associated with disease progression in the whole cohort. Remarkably, level differentials of KLK5-8 and 10-11 strongly impacted disease progression even in patients with residual tumor mass ≤10 mm; hence, the observed impact of level differentials in KLK5-7 and 10 on disease progression was not simply attributable to their association with surgical success. CONCLUSION Since they impact both surgical outcome and survival in advanced ovarian cancer, measurement of level differentials could support clinical decisions on surgical and systemic therapy or help in patient selection for novel targeted therapies.
Collapse
Affiliation(s)
- J Dorn
- Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany.
| | - N Harbeck
- Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
| | - R Kates
- Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
| | - A Gkazepis
- Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
| | - A Scorilas
- Department of Biochemistry and Molecular Biology, National Center for Scientific Research 'Demokritos', University of Athens, Athens, Greece
| | - A Soosaipillai
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
| | - E Diamandis
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
| | - M Kiechle
- Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
| | - B Schmalfeldt
- Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
| | - M Schmitt
- Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
| |
Collapse
|
3
|
Magdolen V, Viktorov P, Holzscheiter L, Arlt M, Soosaipillai A, Talieri M, Diamandis E, Schmitt M, Krüger A, Prezas P. ID: 119 Effects of overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 on the malignant phenotype of ovarian cancer cells. J Thromb Haemost 2006. [DOI: 10.1111/j.1538-7836.2006.00119.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Schmalfeldt B, Kates R, Dorn J, Scorilas A, Grass L, Soosaipillai A, Diamandis E, Kiechle M, Schmitt M, Harbeck N. Impact of proteolytic factors on surgical success and survival in ovarian cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Schmalfeldt
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - R. Kates
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - J. Dorn
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - A. Scorilas
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - L. Grass
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - A. Soosaipillai
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - E. Diamandis
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - M. Kiechle
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - M. Schmitt
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| | - N. Harbeck
- Klin r. d. Isar, Tech Univ of Munich, Munich, Germany; NCS Research Demokritos, N. Univ of Athens, Athens, Greece; Univ of Toronto, Mount Sinai Hosp, Toronto, ON, Canada
| |
Collapse
|
5
|
Abstract
OBJECTIVE To investigate serum prostate specific antigen (PSA) levels with age and sex in childhood. SUBJECTS AND METHODS This prospective study included 205 children (123 boys, 82 girls; mean age 59.27 months, sd 3.78, range 2 days to 204 months) with no urogenital or endocrine disorders. PSA levels were measured using a highly sensitive, "third-generation" PSA (time-resolved immunofluorometric) assay, able to detect PSA levels of > or = 1 ng/L (0.001 ng/mL). Children were divided into four groups by age, i.e. A (0-12 months; 34 boys/20 girls); B (13-48, 37/21); C (49-144, 41/32); and D (> 144, 11/9). The data were analysed statistically using analysis of variance. RESULTS An accurate measurement of PSA was possible in both sexes using the assay. The median (sd, range) PSA level in boys was 38.41 (1.318, 1-2768) ng/L, and in girls 4.059 (1.392, 1-287) ng/L. There were no significant differences between girls at all age groups, or between the sexes for groups A-C, but levels were significantly higher in boys in group D (30 times that in girls), at 142.59 (1.53) and 4.85 (1.58) ng/L (P < 0.01). CONCLUSIONS PSA levels do not differ significantly between boys and girls until 12 years old, after which there is a significant and steep increase in PSA in boys, reflecting the development of the prostate. Assessing PSA in children could be used as a potential marker in the diagnosis and follow-up of urogenital disorders.
Collapse
Affiliation(s)
- A Antoniou
- Department of Paediatric Urology, Aghia Sophia Children's Hospital, Athens, Greece.
| | | | | | | | | |
Collapse
|
6
|
Katsaros D, Fracchioli S, de la Longrais IAR, Puopolo M, Yousef GM, Vergote I, van der Zee AG, Diamandis E. HUMAN KALLIKREINS (HKS) AS NOVEL SERUM BIOMARKERS IN OVARIAN CANCER. Int J Gynecol Cancer 2003. [DOI: 10.1136/ijgc-00009577-200303001-00066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
7
|
Fracchioli S, Borgono CA, de la Longrais IAR, Puopolo M, Richiardi G, Arisio R, Diamandis E, Katsaros D. TISSUE HUMAN KALLIKREIN 11 (HK11) EVALUATION. Int J Gynecol Cancer 2003. [DOI: 10.1136/ijgc-00009577-200303001-00038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
8
|
Fracchioli S, Yousef GM, de la Longrais IAR, Puopolo M, Richiardi G, Danese S, Diamandis E, Katsaros D. HUMAN KALLIKREIN GENE 15 (KLK15) EXPRESSION. Int J Gynecol Cancer 2003. [DOI: 10.1136/ijgc-00009577-200303001-00065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
9
|
Becker C, Noldus J, Diamandis E, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 2001; 38:357-99. [PMID: 11720279 DOI: 10.1080/20014091084236] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Prostate-specific antigen (PSA or hK3) is a glandular kallikrein with abundant expression in the prostate that is widely used to detect and monitor prostate cancer (PCa), although the serum level is frequently elevated also in benign and inflammatory prostatic diseases. PSA testing is useful for early detection of localized PCa and for the detection of disease recurrence after treatment. However, PSA has failed to accurately estimate cancer volume and preoperative staging. There is no PSA level in serum that definitively distinguishes men with benign conditions from those with prostate cancer, although PCa is rare in men with PSA levels in serum < 2.0 ng/ml. This prompted searches for enhancing parameters to combine with PSA testing, such as PSA density, PSA velocity, and age-specific reference ranges. Due to the protease structure, PSA occurs in different molecular forms in serum and their concentrations vary according to the type of prostatic disease. Human glandular kallikrein 2 (hK2) is very similar to PSA, but expressed at higher levels in prostate adenocarcinoma than in normal prostate epithelium. Blood testing for hK2 combined with different PSA forms improves discrimination of men with benign prostatic disease from those with prostate cancer. Many data have also been reported on the extra-prostatic expression of both PSA and hK2, and it is now believed that they may both have functions in tissues outside the prostate.
Collapse
Affiliation(s)
- C Becker
- Dept. of Clinical Chemistry, Lund University, Malmö University Hospital, Malmö, Sweden.
| | | | | | | |
Collapse
|
10
|
Bulmer B, Ward G, Diamandis E, Nicol D, Clements J. Prostaglandin D synthase does not produce prostate-specific antigen cross-reactivity in renal cell carcinoma. Clin Chem 2001; 47:607-8. [PMID: 11238325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
11
|
Bjartell A, Paju A, Stenman UH, Väisänen V, Aumüller G, Diamandis E, Becker C, Lilja H. Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues. Prostate Cancer Prostatic Dis 2000; 3:S7. [PMID: 12497117 DOI: 10.1038/sj.pcan.4500431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A Bjartell
- Department of Urology, Malmö University Hospital, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Comay D, Cauch-Dudek K, Hemphill D, Diamandis E, Wanless I, Heathcote EJ. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis? Dig Dis Sci 2000; 45:2018-21. [PMID: 11117577 DOI: 10.1023/a:1005548126211] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
Antibodies to carbonic anhydrase II (CAII) have been reported to be specific to anti-mitochondrial antibody (AMA)-negative primary biliary cirrhosis (PBC). We examined whether antibodies to CAII are specific for AMA-negative PBC or a nonspecific response in autoimmune liver disease. Antibody assays to CAII, by western immunoblot (dilution 1:200), were performed on sera from 16 AMA-negative PBC patients, 21 AMA-positive PBC patients, 21 autoimmune hepatitis type 1 (AIH) patients, and 18 alcoholic liver disease (ALD) patients. CAII antibody activity was found in 8 of 16 (50%) of the AMA-negative PBC patients, 9 of 21 (43%) of the AMA-positive PBC group, 10 of 21 (48%) of the AIH group, and in 3 of 18 (17%) of the ALD control group. There was no difference in the prevalence of CAII antibody reactivity between the AMA-negative PBC, AMA-positive PBC, and AIH groups. In conclusion, we determined that CAII antibodies are detected with equal frequency in AMA-positive PBC and AIH. Given that CAII antibodies have been reported in other nonhepatic autoimmune diseases, we conclude that CAII antibodies are likely a nonspecific marker of autoimmunity rather than specific for AMA-negative PBC.
Collapse
Affiliation(s)
- D Comay
- Department of Medicine, University of Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
13
|
Sauter ER, Ehya H, Babb J, Diamandis E, Daly M, Klein-Szanto A, Sigurdson E, Hoffman J, Malick J, Engstrom PF. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. Br J Cancer 1999; 81:1222-7. [PMID: 10584885 PMCID: PMC2374332 DOI: 10.1038/sj.bjc.6690832] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We previously demonstrated that nipple aspirate fluid (NAF) can be obtained from virtually all non-Asian women between the ages of 30 and 72. The focus of this report is to (1) determine the association of candidate markers of breast cancer risk in NAF obtained from fresh mastectomy specimens with residual breast carcinoma, and (2) evaluate the association of the markers with breast tumour progression. Nipple aspiration was performed on 97 specimens. Cytology, DNA index (including % hypertetraploid cells), cell cycle parameters (S phase fraction, % cells in G2/M), prostate-specific antigen (PSA), epidermal growth factor (EGF), testosterone, carcinoembryonic antigen (CEA) and prostaglandin D synthase (PGDS) were evaluated in NAF for their association with (1) residual ductal carcinoma in situ (DCIS) or invasive cancer, and (2) pathologic tumour size. NAF was obtained from 99% (96/97) of specimens. Atypical and malignant NAF cytology were significantly associated with residual DCIS or invasive cancer (P = 0.001) and with larger tumours (P = 0.004). One hundred per cent and 88% of subjects with malignant and atypical NAF cytology, respectively, had residual carcinoma. The percentage of cells in G2/M and DNA index were associated both with risk of residual carcinoma (P = 0.01 for each) and larger tumour size (DNA index, P = 0.03; G2/M, P = 0.05), although neither biomarker improved the ability of NAF cytology, to predict residual breast cancer. Higher DNA index was associated with atypical cytology (P = 0.0001). In summary, atypical and malignant NAF cytology are associated with larger tumour size, and are highly predictive of residual carcinoma after needle or excisional biopsy of the breast.
Collapse
Affiliation(s)
- E R Sauter
- Division of Population Sciences, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Sauter ER, Babb J, Daly M, Engstrom PF, Ehya H, Malick J, Diamandis E. Prostate-specific antigen production in the female breast: association with progesterone. Cancer Epidemiol Biomarkers Prev 1998; 7:315-20. [PMID: 9568787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Prostate-specific antigen (PSA) is produced by the female breast. Prior in vitro evidence suggests that PSA expression in breast epithelial cells is regulated by androgens and progestins but not estrogens. The purpose of this study was to determine whether (a) PSA expression in breast nipple aspirate fluid (NAF) and in serum is influenced by progesterone (PG); (b) the ability to obtain NAF decreases with repeated breast aspirations; and (c) PSA in NAF correlates with abnormal NAF cytology. Eight pre- and three postmenopausal women with no breast cancer risk factors were enrolled in a pilot study and had NAF and serum collected every 3-4 days for a month to evaluate the influence of serum PG, luteinizing hormone, estradiol, and follicle-stimulating hormone on PSA in serum and in NAF. NAF was obtained in 99% (112 of 113) of aspiration visits. Median, mean, and peak NAF but not serum PSA levels were higher in pre- than in postmenopausal subjects. NAF PSA levels were associated with the rise or peak in serum PG in seven of eight premenopausal women (seven of seven with a PG surge) and in zero of three postmenopausal women. Considering all 11 women, there was an association between NAF PSA and PG (P = 0.005) but not luteinizing hormone, estradiol, or follicle-stimulating hormone. NAF volume did not significantly change over time. Atypical hyperplasia (9%) and hyperplasia without atypia (36%) were identified in the NAF of a subset of the subjects. Median, mean, and peak levels of NAF PSA (P = 0.05, 0.05, and 0.10, respectively) were higher in subjects with normal versus hyperplastic cytology. PSA production in the breast increases in association with PG. With aspiration every 3-4 days, NAF volume does not significantly decrease over time. NAF cytology and PSA levels in NAF may help identify women at increased breast cancer risk. Changes in biomarkers of breast cancer risk in NAF (including PSA and cytology) may predate mammographic abnormalities. NAF may, therefore, be useful as a breast cancer screening tool for young women who are not recommended to undergo mammography and as an adjunct to screen women who have mammograms performed.
Collapse
Affiliation(s)
- E R Sauter
- Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. E_Sauter@.fccc.edu
| | | | | | | | | | | | | |
Collapse
|
15
|
Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G, Ross EA, Yu H, Diamandis E. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5:967-70. [PMID: 8959318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Despite the fact that breast cancer is the most common non-cutaneous cancer and a leading cause of cancer deaths in women, accepted markers of breast cancer risk miss up to 40% of these tumors. Moreover, screening methods involving the analysis of tissue or cells are limited by the need for a surgical biopsy. Nipple aspiration is a quick, efficient, noninvasive method to obtain breast epithelial cells, the cells at risk for transformation to carcinoma. Prostate-specific antigen (PSA), a protein thought to be specific to the prostate but recently found in a subset of breast tumors, has been correlated with improved survival. The purpose of this study was to measure PSA in a group of women with increasing breast cancer risk (no risk or family history of breast cancer, precancerous mastopathy, and invasive cancer) and determine if PSA correlates with risk. Nipple aspirate fluid was obtained from the intact breast and from surgical specimens using a modified breast pump. PSA was then measured in the fluid using a highly sensitive and specific immunofluorometric procedure. PSA was found at levels ranging from 0-13,423 ng/g of total protein, and there was a significant relationship between PSA level and breast cancer risk (P = 0.001). That is, all women with no risk factors and 90% of those with a family history had high PSA levels, whereas 68% of subjects with precancerous mastopathy or invasive cancer had low PSA levels. PSA was higher in premenopausal subjects (P = 0.002). After adjusting for the effect of menopausal status, there remained a significant association between PSA and breast cancer risk. These findings suggest that PSA in nipple aspirate fluid may be a useful marker of breast cancer risk.
Collapse
Affiliation(s)
- E R Sauter
- Division of Population Science, Fox Chase Cancer Center, Philadelphia Pennsylvania 19111, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Goldberg DM, Tsang E, Karumanchiri A, Diamandis E, Soleas G, Ng E. Method to assay the concentrations of phenolic constituents of biological interest in wines. Anal Chem 1996; 68:1688-94. [PMID: 8651480 DOI: 10.1021/ac951083i] [Citation(s) in RCA: 191] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
We describe a reversed-phase HPLC method that uses gradient elution and diode array detection to quantitate eight biologically active phenolic constitutions of wine: the cis and trans isomers of resveratrol and their glucosides, catechin, epicatechin, quercetin, and rutin. ODS Hypersil served as the stationary phase; the gradient was formed by acetic acid, methanol and water. Each analysis required an equilibration period of ten minutes and a run time of fourty minutes for completion. Satisfactory peak resolution was achieved following direct injection of a 20-muL sample, and validation was accomplished by on-line spectral comparisons with known standards. Excellent linearity was obtained for all constituents, and the detection limits ranged from 30 mug/L (trans-resveratrol) to 1.5 mg/L (catechin). Recoveries approximated 100% range (95.2-105.5%), and the method provided good precision, with coefficients of variation between 1.17 and 3.38%. All of the phenolics measured were reasonably stable in opened wines protected against sunlight for up to 1 week at room temperature or 4 degrees C, but most showed losses of 10-40% when stored for 6 weeks at either temperature.
Collapse
Affiliation(s)
- D M Goldberg
- Department of Clinical Biochemistry, Banting Institute, University of Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|